Rodney L Decker
Overview
Explore the profile of Rodney L Decker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decker R, Ernest 2nd C, Radtke D, Wang R, Araujo J, Keller S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(6):970-981.
PMID: 38532270
Baricitinib is approved for the treatment of rheumatoid arthritis (RA) in more than 70 countries, and juvenile idiopathic arthritis (JIA) in the European Union. Population pharmacokinetic (PK) models were developed...
2.
Wickremsinhe E, Decker R, Lee L, Lelle E, Carlton L, Keller S, et al.
Bioanalysis
. 2023 Jun;
15(11):621-636.
PMID: 37293791
Managing blood volumes in pediatric studies is challenging and should be minimized where possible. A sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was validated and implemented across two...
3.
Yang E, Deutsch E, Mehmet A, Fayette J, Tao Y, Nabell L, et al.
Radiother Oncol
. 2021 Feb;
157:203-209.
PMID: 33577866
Background And Purpose: This study explored the feasibility of safely combining prexasertib, with cisplatin-radiotherapy (Part A) or cetuximab-radiotherapy (Part B) in patients with previously untreated, locoregionally advanced head and neck...
4.
Villalobos V, Mo G, Agulnik M, Pollack S, Rushing D, Singh A, et al.
Cancer Med
. 2019 Dec;
9(3):882-893.
PMID: 31821732
Background: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet-derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics...
5.
Li L, Zhen E, Decker R, Willis B, Waters D, Liu P, et al.
J Alzheimers Dis
. 2019 Feb;
68(1):137-144.
PMID: 30741684
LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as...
6.
Kilburn L, Kocak M, Decker R, Wetmore C, Chintagumpala M, Su J, et al.
Neuro Oncol
. 2014 Nov;
17(2):303-11.
PMID: 25431212
Background: We sought to estimate the maximum tolerated or recommended phase 2 dose and describe the pharmacokinetics and toxicities of enzastaurin, an oral inhibitor of protein kinase Cβ, in children...